Analyst Ratings For NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE)
Today, NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE) stock was downgraded by Wells Fargo from Outperform ➝ Market Perform to with a price target of $37.00 ➝ $13.00.
Some recent analyst ratings include
- 5/17/2018-Wells Fargo was Downgraded by analysts at Wells Fargo from a “Outperform ➝ Market Perform” rating to a “” rating. They now have a $37.00 ➝ $13.00 price target on the stock.
- 6/9/2017-Cowen Reiterated Rating of Buy.
- On 3/15/2018 Barbara Gayle Duncan, Director, sold 2,000 with an average share price of $28.11 per share and the total transaction amounting to $56,220.00.
- On 3/8/2018 Elizabeth Trehu, Insider, sold 4,545 with an average share price of $25.06 per share and the total transaction amounting to $113,897.70.
- On 3/8/2018 Kimberlee C Drapkin, CFO, sold 5,267 with an average share price of $25.01 per share and the total transaction amounting to $131,727.67.
- On 3/8/2018 Richard /Ca/ Murray, CEO, sold 16,334 with an average share price of $25.10 per share and the total transaction amounting to $409,983.40.
- On 3/5/2018 Elizabeth Trehu, Insider, sold 4,545 with an average share price of $21.50 per share and the total transaction amounting to $97,717.50.
- On 3/5/2018 Kimberlee C Drapkin, CFO, sold 5,267 with an average share price of $21.42 per share and the total transaction amounting to $112,819.14.
- On 3/5/2018 Richard /Ca/ Murray, CEO, sold 16,334 with an average share price of $21.43 per share and the total transaction amounting to $350,037.62.
Recent Trading Activity for NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE)
Shares of NASDAQ:JNCE – Jounce Therapeutics closed the previous trading session at 12.02 down -5.65 31.98% with 4532802 shares trading hands.